Thomas Leist, MD
Neurology · Philadelphia, PANPI 1801816681
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $880,482 of the $1,442,489 with a category attached, or 61.0%. It is spread thinly across 30 manufacturers, the largest accounting for just 15.3%. Reporting peaked in 2019 at $525,261 and has fallen 76.3% since, to $124,443 in 2025. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,303 payments — averaging $1107.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$221K
- EMD Serono, Inc.$218K
- Bristol Myers Squibb$196K
- Genentech USA, Inc.$166K
- Amgen$166K
- Sanofi$116K
- plus $360K from 24 others
Across 541 payments — averaging $8010.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3M
- Bristol Myers Squibb$275K
- Roche Products Limited$249K
- Biogen$208K
- Genentech, Inc.$175K
- AbbVie$136K
- plus $331K from 10 others
What the payments were for
- Consulting fees$381,94726%
- Speaking & faculty fees$880,48261%
- Travel & lodging$111,0258%
- Food & beverage$30,4482%
- Education$35,8532%
- Gifts$2,7330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 197 | $221,334 |
| EMD Serono, Inc. | 214 | $217,700 |
| Bristol Myers Squibb | 148 | $195,743 |
| Genentech USA, Inc. | 114 | $165,819 |
| Amgen(2 entities) | 162 | $165,673 |
| Sanofi | 103 | $115,846 |
| TG Therapeutics, Inc. | 80 | $85,441 |
| E.r. Squibb & Sons, L.L.C. | 51 | $68,097 |
| Novartis | 79 | $67,658 |
| AstraZeneca | 49 | $52,857 |
| Sanofi-aventis U.S. LLC | 10 | $26,456 |
| Teva Pharmaceuticals USA, Inc. | 13 | $18,934 |
| Genentech, Inc. | 5 | $14,668 |
| Janssen Global Services, LLC | 8 | $9,323 |
| Johnson & Johnson | 7 | $6,005 |
| Hoffmann-la Roche Limited | 1 | $4,000 |
| Janssen Scientific Affairs, LLC | 2 | $3,240 |
| F. Hoffmann-la Roche AG | 2 | $1,493 |
| Merck Kgaa | 1 | $820 |
| AbbVie | 32 | $510 |
| Actelion Pharmaceuticals, Ltd | 4 | $346 |
| Vanda Pharmaceuticals Inc. | 6 | $169 |
| ANI Pharmaceuticals, Inc. | 3 | $85 |
| Lilly USA, LLC | 3 | $75 |
| Merz Pharmaceuticals, LLC | 2 | $64 |
| Sumitomo Pharma America, Inc. | 3 | $57 |
| Cycle Pharmaceuticals Inc | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Acorda Therapeutics, Inc | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPLIZNA$149,351
- Ozanimod$128,505
- Mavenclad$120,999
- OCREVUS$104,931
- BRIUMVI$77,931
- ZEPOSIA$65,765
- LEMTRADA$42,690
- AUBAGIO$34,174
- KESIMPTA$26,272
- NO PRODUCT DISCUSSED$22,066
- COPAXONE$16,791
- Evobrutinib$14,280
- Vumerity$13,141
- TYSABRI$10,665
- TECFIDERA$10,665
- ULTOMIRIS$9,870
- GILENYA$8,674
- Non-Covered Product$6,846
- Ponvory$5,340
- MAYZENT$4,264
How this compares
$1,442,489 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 97 | $900,631 |
| AubagioTeriflunomide | 53 | $492,006 |
| Teriflunomide | 122 | $321,499 |
| CopaxoneGlatiramer Acetate | 38 | $267,282 |
| EnspryngSatralizumab-Mwge | 12 | $223,995 |
| Glatiramer Acetate | 63 | $178,797 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 20 | $156,532 |
| GlatopaGlatiramer Acetate | 31 | $103,216 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $103,133 |
| Dalfampridine ErDalfampridine | 144 | $97,440 |
| Dimethyl Fumarate | 38 | $61,700 |
| Nurtec OdtRimegepant Sulfate | 11 | $21,950 |
| FingolimodFingolimod Hcl | 16 | $11,484 |
| Baclofen | 244 | $8,342 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $6,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $115,846 | $492,00653 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $18,934 | $267,28238 claims |
| Genentech USA, Inc.Enspryng | $165,819 | $223,99512 claims |
| BiogenAvonex (4 Pack) | $221,334 | $103,13313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Jill Giordano FarmerPhiladelphia$1.2M
- Stephanie Nahas-GeigerPhiladelphia$786K
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Joseph BergerPhiladelphia$384K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
- Michelle DoughertyPhiladelphia$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.